Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms

Brain, Behavior, and Immunity

Volumn 51, Issue , 2016, Pages 47-55

  Aeinehband, Shahin ^a   Brenner, Philip ^a   Ståhl, Sara ^a   Bhat, Maria ^a,b   Fidock, Mark D ^b   Khademi, Mohsen ^a   Olsson, Tomas ^a   Engberg, Göran ^c   Jokinen, Jussi ^a,d   Erhardt, Sophie ^c   Piehl, Fredrik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SCIENCE FOR LIFE LABORATORY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

Cerebrospinal fluid; Depression; Kynurenine pathway; Multiple sclerosis; Progressive MS

Indexed keywords

KYNURENIC ACID; KYNURENINE; QUINOLINIC ACID; TRYPTOPHAN;

ADULT; ARTICLE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MENTAL DISEASE; METABOLITE; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; NEUROLOGIC DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; RELAPSE; REMISSION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; CEREBROSPINAL FLUID; COMPLICATION; MIDDLE AGED;

ADULT; DISEASE PROGRESSION; FEMALE; HUMANS; KYNURENINE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; TRYPTOPHAN;

EID: 84937946456     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.07.016     Document Type: Article

References (57)

1. Agudelo, L.Z., Femenia, T., Orhan, F., Porsmyr-Palmertz, M., Goiny, M., Martinez-Redondo, V., Correia, J.C., Izadi, M., Bhat, M., Schuppe-Koistinen, I., Pettersson, A.T., Ferreira, D.M., Krook, A., Barres, R., Zierath, J.R., Erhardt, S., Lindskog, M., Ruas, J.L., Skeletal muscle PGC-1alpha1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell 159 (2014), 33–45.
2. Amirkhani, A., Rajda, C., Arvidsson, B., Bencsik, K., Boda, K., Seres, E., Markides, K.E., Vecsei, L., Bergquist, J., Interferon-beta affects the tryptophan metabolism in multiple sclerosis patients. Eur. J. Neurol. 12 (2005), 625–631.
3. Andine, P., Lehmann, A., Ellren, K., Wennberg, E., Kjellmer, I., Nielsen, T., Hagberg, H., The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection. Neurosci. Lett. 90 (1988), 208–212.
4. Atlas, A., Franzen-Rohl, E., Soderlund, J., Jonsson, E.G., Samuelsson, M., Schwieler, L., Skoldenberg, B., Engberg, G., Sustained elevation of kynurenic Acid in the cerebrospinal fluid of patients with herpes simplex virus type 1 encephalitis. Int. J. Tryptophan Res. 6 (2013), 89–96.
5. Bay-Richter, C., Linderholm, K.R., Lim, C.K., Samuelsson, M., Traskman-Bendz, L., Guillemin, G.J., Erhardt, S., Brundin, L., A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain Behav. Immun. 43 (2015), 110–117.
6. Behan, W.M., McDonald, M., Darlington, L.G., Stone, T.W., Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br. J. Pharmacol. 128 (1999), 1754–1760.
7. Birch, P.J., Grossman, C.J., Hayes, A.G., Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur. J. Pharmacol. 154 (1988), 85–87.
8. Cammer, W., Oligodendrocyte killing by quinolinic acid in vitro. Brain Res. 896 (2001), 157–160.
9. Campbell, B.M., Charych, E., Lee, A.W., Moller, T., Kynurenines in CNS disease: regulation by inflammatory cytokines. Front. Neurosci., 8, 2014, 12.
10. Chen, Y., Meininger, V., Guillemin, G.J., Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors. Cent. Nerv. Syst. Agents Med. Chem. 9 (2009), 32–39.
11. Chen, Y., Stankovic, R., Cullen, K.M., Meininger, V., Garner, B., Coggan, S., Grant, R., Brew, B.J., Guillemin, G.J., The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotox. Res. 18 (2010), 132–142.
12. Chiarugi, A., Cozzi, A., Ballerini, C., Massacesi, L., Moroni, F., Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis. Neuroscience 102 (2001), 687–695.
13. Confavreux, C., Vukusic, S., Natural history of multiple sclerosis: a unifying concept. Brain 129 (2006), 606–616.
14. Dickens, A.M., Larkin, J.R., Griffin, J.L., Cavey, A., Matthews, L., Turner, M.R., Wilcock, G.K., Davis, B.G., Claridge, T.D., Palace, J., Anthony, D.C., Sibson, N.R., A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. Neurology 83 (2014), 1492–1499.
15. DiNatale, B.C., Murray, I.A., Schroeder, J.C., Flaveny, C.A., Lahoti, T.S., Laurenzana, E.M., Omiecinski, C.J., Perdew, G.H., Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol. Sci. 115 (2010), 89–97.
16. Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindstrom, L.H., Engberg, G., Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 313 (2001), 96–98.
17. Erhardt, S., Lim, C.K., Linderholm, K.R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T.T., Traskman-Bendz, L., Guillemin, G.J., Brundin, L., Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 38 (2013), 743–752.
18. Fisk, J.D., Pontefract, A., Ritvo, P.G., Archibald, C.J., Murray, T.J., The impact of fatigue on patients with multiple sclerosis. Can. J. Neurol. Sci. 21 (1994), 9–14.
19. Flanagan, E.M., Erickson, J.B., Viveros, O.H., Chang, S.Y., Reinhard, J.F. Jr., Neurotoxin quinolinic acid is selectively elevated in spinal cords of rats with experimental allergic encephalomyelitis. J. Neurochem. 64 (1995), 1192–1196.
20. Grilli, M., Raiteri, L., Patti, L., Parodi, M., Robino, F., Raiteri, M., Marchi, M., Modulation of the function of presynaptic alpha7 and non-alpha7 nicotinic receptors by the tryptophan metabolites, 5-hydroxyindole and kynurenate in mouse brain. Br. J. Pharmacol. 149 (2006), 724–732.
21. Heyes, M.P., Saito, K., Crowley, J.S., Davis, L.E., Demitrack, M.A., Der, M., Dilling, L.A., Elia, J., Kruesi, M.J., Lackner, A., et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115:Pt 5 (1992), 1249–1273.
22. Kessler, M., Baudry, M., Lynch, G., Quinoxaline derivatives are high-affinity antagonists of the NMDA receptor-associated glycine sites. Brain Res. 489 (1989), 377–382.
23. Lim, C.K., Brew, B.J., Sundaram, G., Guillemin, G.J., Understanding the roles of the kynurenine pathway in multiple sclerosis progression. Int. J. Tryptophan Res. 3 (2010), 157–167.
24. Maes, M., Leonard, B.E., Myint, A.M., Kubera, M., Verkerk, R., The new ‘5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35 (2011), 702–721.
25. Mahad, D.H., Trapp, B.D., Lassmann, H., Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 14 (2015), 183–193.
26. Mandi, Y., Vecsei, L., The kynurenine system and immunoregulation. J. Neural Transm. 119 (2012), 197–209.
27. McDonald, W.I., Compston, A., Edan, G., Goodkin, D., Hartung, H.P., Lublin, F.D., McFarland, H.F., Paty, D.W., Polman, C.H., Reingold, S.C., Sandberg-Wollheim, M., Sibley, W., Thompson, A., van den Noort, S., Weinshenker, B.Y., Wolinsky, J.S., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001), 121–127.
28. Munn, D.H., Zhou, M., Attwood, J.T., Bondarev, I., Conway, S.J., Marshall, B., Brown, C., Mellor, A.L., Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281 (1998), 1191–1193.
29. Myint, A.M., Kim, Y.K., Verkerk, R., Scharpe, S., Steinbusch, H., Leonard, B., Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 98 (2007), 143–151.
30. Nilsson, L.K., Linderholm, K.R., Engberg, G., Paulson, L., Blennow, K., Lindstrom, L.H., Nordin, C., Karanti, A., Persson, P., Erhardt, S., Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr. Res. 80 (2005), 315–322.
31. Olsson, S.K., Sellgren, C., Engberg, G., Landen, M., Erhardt, S., Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord. 14 (2012), 719–726.
32. Parsons, C.G., Danysz, W., Quack, G., Hartmann, S., Lorenz, B., Wollenburg, C., Baran, L., Przegalinski, E., Kostowski, W., Krzascik, P., Chizh, B., Headley, P.M., Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J. Pharmacol. Exp. Ther. 283 (1997), 1264–1275.
33. Perkins, M.N., Stone, T.W., An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247 (1982), 184–187.
34. Piehl, F., A changing treatment landscape for multiple sclerosis: challenges and opportunities. J. Intern. Med. 275 (2014), 364–381.
35. Raison, C.L., Dantzer, R., Kelley, K.W., Lawson, M.A., Woolwine, B.J., Vogt, G., Spivey, J.R., Saito, K., Miller, A.H., CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 15 (2010), 393–403.
36. Ratzer, R., Sondergaard, H.B., Christensen, J.R., Bornsen, L., Borup, R., Sorensen, P.S., Sellebjerg, F., Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis. Mult. Scler. 19 (2013), 1841–1848.
37. Rejdak, K., Bartosik-Psujek, H., Dobosz, B., Kocki, T., Grieb, P., Giovannoni, G., Turski, W.A., Stelmasiak, Z., Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci. Lett. 331 (2002), 63–65.
38. Rejdak, K., Petzold, A., Kocki, T., Kurzepa, J., Grieb, P., Turski, W.A., Stelmasiak, Z., Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis. J. Neural Transm. 114 (2007), 1011–1015.
39. Reynolds, D.S., Morton, A.J., Changes in blood–brain barrier permeability following neurotoxic lesions of rat brain can be visualised with trypan blue. J. Neurosci. Methods 79 (1998), 115–121.
40. Rios, C., Santamaria, A., Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem. Res. 16 (1991), 1139–1143.
41. Santamaria, A., Galvan-Arzate, S., Lisy, V., Ali, S.F., Duhart, H.M., Osorio-Rico, L., Rios, C., St'astny, F., Quinolinic acid induces oxidative stress in rat brain synaptosomes. NeuroReport 12 (2001), 871–874.
42. Sapko, M.T., Guidetti, P., Yu, P., Tagle, D.A., Pellicciari, R., Schwarcz, R., Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: implications for Huntington's disease. Exp. Neurol. 197 (2006), 31–40.
43. Sas, K., Robotka, H., Toldi, J., Vecsei, L., Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J. Neurol. Sci. 257 (2007), 221–239.
44. Sathyasaikumar, K.V., Stachowski, E.K., Wonodi, I., Roberts, R.C., Rassoulpour, A., McMahon, R.P., Schwarcz, R., Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr. Bull. 37 (2011), 1147–1156.
45. Schwarcz, R., Rassoulpour, A., Wu, H.Q., Medoff, D., Tamminga, C.A., Roberts, R.C., Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50 (2001), 521–530.
46. Schwarcz, R., Guidetti, P., Sathyasaikumar, K.V., Muchowski, P.J., Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease. Prog. Neurobiol. 90 (2010), 230–245.
47. Schwarcz, R., Bruno, J.P., Muchowski, P.J., Wu, H.Q., Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 13 (2012), 465–477.
48. Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., Dunbar, G.C., The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59:20 (1998), 22–33.
49. St'astny, F., Skultetyova, I., Pliss, L., Jezova, D., Quinolinic acid enhances permeability of rat brain microvessels to plasma albumin. Brain Res. Bull. 53 (2000), 415–420.
50. Steiner, J., Bogerts, B., Sarnyai, Z., Walter, M., Gos, T., Bernstein, H.G., Myint, A.M., Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: potential role of glial NMDA receptor modulators and impaired blood–brain barrier integrity. World J. Biol. Psychiatry 13 (2012), 482–492.
51. Stone, T.W., Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 45 (1993), 309–379.
52. Svanborg, P., Asberg, M., A new self-rating scale for depression and anxiety states based on the Comprehensive Psychopathological Rating Scale. Acta Psychiatr. Scand. 89 (1994), 21–28.
53. Tavares, R.G., Tasca, C.I., Santos, C.E., Wajner, M., Souza, D.O., Dutra-Filho, C.S., Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain. NeuroReport 11 (2000), 249–253.
54. Tavares, R.G., Tasca, C.I., Santos, C.E., Alves, L.B., Porciuncula, L.O., Emanuelli, T., Souza, D.O., Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem. Int. 40 (2002), 621–627.
55. Ting, K.K., Brew, B.J., Guillemin, G.J., Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J. Neuroinflammation, 6, 2009, 36.
56. Vecsei, L., Szalardy, L., Fulop, F., Toldi, J., Kynurenines in the CNS: recent advances and new questions. Nat. Rev. Drug Discov. 12 (2013), 64–82.
57. Wang, J., Simonavicius, N., Wu, X., Swaminath, G., Reagan, J., Tian, H., Ling, L., Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J. Biol. Chem. 281 (2006), 22021–22028.